Literature DB >> 23868505

Evaluations of therapeutic efficacy of intravitreal injected polylactic-glycolic acid microspheres loaded with triamcinolone acetonide on a rabbit model of uveitis.

Wenchang Li1, Bing He, Wenbing Dai, Qiang Zhang, Yuling Liu.   

Abstract

Conventional treatments of uveitis are not ideal because of the short period of therapeutic efficacy. In the present study, biodegradable polylactic-glycolic acid microspheres loaded with triamcinolone acetonide (TA) were prepared to achieve sustained drug release and their therapeutic efficacy was investigated on a rabbit model of uveitis. TA-loaded microspheres (TA-MS) were prepared by the solvent evaporation method and characterized for encapsulation efficiency, particle size, morphology and in vitro release. The therapeutic efficacy was studied on the rabbit experimental uveitis model based on scoring of the inflammation, aqueous leukocyte counting, aqueous protein determination and histological examination. The TA-MS exhibited smooth and intact surfaces with an average diameter of 50.87 μm. The drug-loading coefficient and encapsulation efficiency were 15.2 ± 0.6 % and 91.24 ± 3.77 %, respectively. The drug release from TA-MS lasted up to 87 days, but only 46 days for TA suspension. The change in surface morphology also showed sustained drug release from TA-MS. TA-MS exhibited improved therapeutic efficacy in lipopolysaccharide -induced uveitis compared to TA suspension, especially in regard to the inhibition of inflammation. The TA-MS had a longer-term therapeutic effect on intraocular inflammation in LPS-induced uveitis in rabbits compared to TA suspension. The results suggested that TA-MS can be developed as a potential sustained-release system for the treatment of uveitis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23868505     DOI: 10.1007/s10792-013-9829-0

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  34 in total

Review 1.  The possible impact of uveitis in blindness: a literature survey.

Authors:  M S Suttorp-Schulten; A Rothova
Journal:  Br J Ophthalmol       Date:  1996-09       Impact factor: 4.638

2.  Coinduction of nitric oxide synthase and arginine metabolic enzymes in endotoxin-induced uveitis rats.

Authors:  Takahisa Koga; Yasuo Koshiyama; Tomomi Gotoh; Naoko Yonemura; Akira Hirata; Hidenobu Tanihara; Akira Negi; Masataka Mori
Journal:  Exp Eye Res       Date:  2002-12       Impact factor: 3.467

3.  Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit.

Authors:  J M Leeds; S P Henry; L Truong; A Zutshi; A A Levin; D Kornbrust
Journal:  Drug Metab Dispos       Date:  1997-08       Impact factor: 3.922

4.  Biodegradable microspheres for vitreoretinal drug delivery.

Authors:  R Herrero-Vanrell; M F Refojo
Journal:  Adv Drug Deliv Rev       Date:  2001-10-31       Impact factor: 15.470

Review 5.  Triamcinolone acetonide in ocular therapeutics.

Authors:  C M Jermak; J T Dellacroce; J Heffez; G A Peyman
Journal:  Surv Ophthalmol       Date:  2007 Sep-Oct       Impact factor: 6.048

Review 6.  Intravitreal steroids for macular edema: the past, the present, and the future.

Authors:  Matthew A Cunningham; Jeffrey L Edelman; Shalesh Kaushal
Journal:  Surv Ophthalmol       Date:  2008 Mar-Apr       Impact factor: 6.048

7.  A review of the development of a vehicle for localized and controlled drug delivery for implantable biosensors.

Authors:  Upkar Bhardwaj; Fotios Papadimitrakopoulos; Diane J Burgess
Journal:  J Diabetes Sci Technol       Date:  2008-11

8.  Efficacy and safety of microspheres of cyclosporin A, a new systemic formulation, to prevent corneal graft rejection in rats.

Authors:  Ana I Vallelado; M Isabel López; Margarita Calonge; Alejandro Sánchez; M José Alonso
Journal:  Curr Eye Res       Date:  2002-01       Impact factor: 2.424

Review 9.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

10.  Sustained release intraocular drug delivery devices for treatment of uveitis.

Authors:  Nahid Haghjou; Masoud Soheilian; Mohammad Jafar Abdekhodaie
Journal:  J Ophthalmic Vis Res       Date:  2011-10
View more
  4 in total

1.  Sirolimus-Loaded Intravitreal Implant for Effective Treatment of Experimental Uveitis.

Authors:  Mayara Rodrigues Brandão De Paiva; Daniel Vítor Vasconcelos-Santos; Lorena Carla Vieira; Sílvia Ligório Fialho; Armando Silva-Cunha
Journal:  AAPS PharmSciTech       Date:  2021-01-06       Impact factor: 3.246

2.  Porous Core/Dense Shell PLA Microspheres Embedded with High Drug Loading of Bupivacaine Crystals for Injectable Prolonged Release.

Authors:  Jinghua Xu; Yanjie Bai; Xuehui Li; Zhenping Wei; Lu Sun; Hongdan Yu; Hui Xu
Journal:  AAPS PharmSciTech       Date:  2021-01-06       Impact factor: 3.246

3.  Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells.

Authors:  Siva P Kambhampati; Manoj K Mishra; Panagiotis Mastorakos; Yumin Oh; Gerard A Lutty; Rangaramanujam M Kannan
Journal:  Eur J Pharm Biopharm       Date:  2015-02-19       Impact factor: 5.571

4.  Development of Triamcinolone Acetonide-Loaded Microemulsion as a Prospective Ophthalmic Delivery System for Treatment of Uveitis: In Vitro and In Vivo Evaluation.

Authors:  Alaa Mahran; Sayed Ismail; Ayat A Allam
Journal:  Pharmaceutics       Date:  2021-03-25       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.